TG Therapeutics, Inc. (TGTX) Stock Forecast
TGTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 8 analysts
- Price target
- $69.71 average of analyst targets
- Upside to target
- +29.2% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $0.37
- 52-week range
- $26.94 – $59.06
TGTX analyst ratings
8 analystsNumber of analysts at each rating.
TGTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TGTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.26 | $0.19 | $0.35 | $0.16 | +60.0% | 4 |
| Current fiscal year (2026) | $0.95 | $0.70 | $1.32 | $2.77 | −65.7% | 4 |
| Next fiscal year (2027) | $2.71 | $2.16 | $3.96 | $0.95 | +185.1% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TGTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $245.4M | $232.0M | $255.0M | +51.8% | 8 |
| Current fiscal year (2026) | $960.3M | $950.0M | $982.6M | +55.8% | 8 |
| Next fiscal year (2027) | $1.32B | $1.22B | $1.44B | +37.4% | 8 |
TGTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TGTX revenue: reported and forecast
TGTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.43 | $0.34 | $0.33 | $0.33 | $0.26 | −40.8% | 0 up · 2 down |
| Current fiscal year (2026) | $1.61 | $1.00 | $0.95 | $0.95 | $0.95 | −41.1% | 0 up · 3 down |
| Next fiscal year (2027) | $3.28 | $3.13 | $2.96 | $2.71 | $2.71 | −17.5% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TGTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TGTX beat in 4 of 12.
What analysts expect from TGTX
8 analysts cover TG Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $69.71, 29.2% above the latest close of $53.97. Analysts expect earnings of $0.95 per share for 2026, −65.7% from a year earlier. For 2027 the average estimate is $2.71 per share on revenue of $1.3 billion. TG Therapeutics beat the EPS estimate in 4 of the last 12 quarters.
Related: TGTX income statement, TGTX key metrics, TGTX chart. See the TGTX stock overview for the latest quote and news.
TGTX forecast FAQ
What is TG Therapeutics's price target?
The average analyst price target for TG Therapeutics is $69.71, 29.2% above the latest close of $53.97.
Is TG Therapeutics a buy, hold or sell?
Of 8 analysts covering TG Therapeutics, 6 rate it a strong buy, 1 a buy, 0 a hold, 1 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is TG Therapeutics's EPS forecast?
Analysts forecast $0.95 per share for 2026 (range $0.70 to $1.32); for 2027 the estimate is $2.71.
What is TG Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $960.3 million, growth of 55.8%; for 2027 it is $1.3 billion.
When does TG Therapeutics report earnings?
TG Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens; the EPS estimate is $0.37.
Does TG Therapeutics usually beat earnings estimates?
TG Therapeutics reported EPS at or above the analyst estimate in 4 of the last 12 quarters.